Antiviral PK 2018 – Presentations

 

Tuesday 22 MayWednesday 23 MayThursday 24 May
 

TUESDAY, MAY 22, 2018

 
 Session 1: New technologies and formulations
 
  Thomas, David 2016 120x160How to End the Global HCV Epidemic - the role of injectables
David Thomas, MD
 
  koup, richard 2015Clinical Development of Long-Acting Broadly Neutralizing Monoclonal Antibodies: Lessons Learned Thus Far
Richard Koup, MD
 
  Becker, Stephen 2014Viral Dynamics and the Search for an HIV Cure 
Steven Becker, MD
 
  Back to top 
 

WEDNESDAY, MAY 23, 2018

 
 Session 2: Hepatitis related topic
 
  Burger,David 2018, 120 x 160The use of DAA’s in pregnancy in HCV infected mothers
David Burger, PharmD
 
  Thomas, David 2016 120x160Clinical case presentation
David Thomas, MD
 
  

Cressey, Tim 2017 120x160Tenofovir exposure during pregnancy and postpartum in hepatitis B mono-infected women on TDF monotherapy compared to HIV-infected women on TDF-containing antiretroviral therapy

Tim Cressey, PhD

 1
  

Intracellular 007-TP Concentrations are Associated with Gradients of Adherence to Ledipasvir/Sofosbuvir

Leah Jimmerson, PhD

 2
  

A Pharmacometabolomics Approach for Predicting Tenofovir diphosphate (TFV-DP) Concentrations in Dried Blood Spots (DBS)

Mustafa Ibrahim

 3
   
 Session 3: Round Table discussion: validation of Physiologically based pharmacokinetic (PBPK) modeling 
 
  Gobburu, Joga 2014_120Application of Physiologically based pharmacokinetic (PBPK) Modelling to Drug Development Decisions
Joga Gobburu, PhD, MBA 
 
  Yeo, Karen 2018 120 x 160Application of PBPK modelling for assessment of DDI liability in combination therapies
(Not available)

Karen Yeo, PhD
 
  Zhang, Xinxin 2016_120Physiologically based pharmacokinetic modeling and simulation in drug product development and review 
Xinyuan Zhang, PhD
 
   
 Session 4: Towards Precision Medicine 
 
  Haas_David 2011How/when will pharmacogenomics translate into improved clinical care?
David Haas, MD
 
  Calcagno, Andrea 120 x 160Last advances in HIV pharmacogenomics 
Andrea Calcagno, MD
 
  

SLC22a2 genetic variants and dolutegravir trough concentrations correlate with specific psychiatric symptoms in hiv-positive patients on dolutegravir

Alberto Borghetti, PhD

 4
  

Age, Inflammation, Blood Brain Barrier Permeability and Single Nucleotide Polymorphisms in Transporters May Influence Cerebrospinal Fluid Antiretrovirals' Concentrations

Andrea Calcagno, MD

 5
   
 SHORT POSTER PRESENTATIONS; "BEST OF POSTERS"
 
  

Assessment of maternal and fetal dolutegravir exposure by integrating ex vivo placental perfusion data and physiologically-based pharmacokinetic modeling

Jolien Freriksen, MSc

 14
  

Does hepatic impairment affect the exposure of monoclonal antibodies? 

Qin Sun, PhD

 15
  

Reduced nevirapine concentrations among HIV-positive women receiving mefloquine for intermittent preventive treatment for malaria control during pregnancy

Richard Haaland

 16
  

Elvitegravir pharmacokinetics during Pregnancy and Postpartum

Angela Colbers, PhD

 17
   
 Session 5: HIV related topic
 
  Di Perri, Giovanni 2016 120x160Clinical Pharmacology of Integrase Inhibitors 
Giovanni di Perri, MD, PhD
 
  Clinical case presentation 
Marta Boffito, PhD
 
  

Pharmacokinetics of Dolutegravir 100 MG once-daily with Rifampicin

Marta Boffito, PhD

 11
  

Pharmacokinetic and virological efficacy of dolutegravir (50 mg BID) containing regimen in association with rifampin in HIV-infected patients using Dried Blood Spot: ANRS-12313 NAMSAL sub-study in Cameroon

Minh Le

 7
  

First report of dolutegravir unbound plasma concentrations during pregnancy in HIV-positive women

Pauline Bollen

 8
 Back to top 
 

THURSDAY, MAY 24, 2018

 
 Session 6: Drug - Drug interactions related session
 
  

Yang, Xinning 2018Update on DDI guidelines of the FDA - in vitro

Xinning Yang, PhD

 
  

Reynolds, Kellie 2017Update on DDI guidelines of the FDA - in vivo

Kellie Reynolds, PharmD

 
  

Medication safety issues associated with currently used first-line antiretroviral regimens in Uganda

Kay Seden

 9
  

Intraindividual comparison of efavirenz, atazanavir, or ritonavir plasma pharmacokinetics before and during 21-days of vaginally administered hormone contraception

Kimberly Scarsi, PharmD, MS

 10
  

Rifabutin (RBT) Decreases Cabotegravir (CAB) Exposure Following Oral Co-administration

Parul Patel, PharmD

 11
  

Rifabutin PK and Safety among HIV/TB–Coinfected Children Receiving Lopinavir

Holly Rawizza, MD

 12
  

Clinical Pharmacology of HIV Pre-Exposure Prophylaxis (PrEP) – Where are we now

Craig Hendrix, MD

 
   
 SHORT POSTER PRESENTATIONS "BEST OF POSTERS" 
 
  

Comparison of 5 online free access expert databases to check drug-drug interactions between antiretroviral drugs and co-prescribed medications from a French cohort of HIV-infected outpatients. 

Minh Le

 18
  

Polypharmacy, drug-drug interactions and potentially inappropriate prescribing in elderly patients of the swiss HIV cohort study
(Not available) 

Catia Marzolini, PharmD, PhD

 19
  

Population Pharmacokinetics and Pharmacokinetics/Pharmacodynamics of Etravirine in HIV-positive Children Ages 1-<6 Years

Mustafa Ibrahim

 20
  

Differential brain tissue penetration of antiretrovirals and fluconazole

Katelyn Pastick

 21
 Back to top